Preventing cancer with vaccines: Progress in the global control of cancer

Cancer Prevention Research

Volumn 5, Issue 1, 2012, Pages 24-29

  Kane, Mark A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BCG VACCINE; CANCER VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPE; COMMUNITY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIPHTHERIA; FATALITY; HAEMOPHILUS INFLUENZAE TYPE B; HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION; INJECTION; LIVER CANCER; LIVER CIRRHOSIS; LUNG CANCER; MEASLES; MUMPS; NOTE; OROPHARYNX CANCER; PALLIATIVE THERAPY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERTUSSIS; POLIOMYELITIS; PRECANCER; PRIORITY JOURNAL; RUBELLA; SMALLPOX; SMOKING; SQUAMOUS CELL CARCINOMA; SYRINGE; TETANUS; TUBERCULOSIS; UTERINE CERVIX CANCER; WART VIRUS; YELLOW FEVER;

CERVIX UTERI; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 84855557781     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0533     Document Type: Note

References (43)

1. World Health Organization. Countries using Hepatitis B vaccine. [cited 2011 Oct 18]. Available from: http://www.who.int/immunization/topics/hepatitis- b/en/index.html.
2. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine 2006;24 Suppl 3:S132-9. (Pubitemid 44293031)
3. Goldstein ST, Zhou FJ, Hadler S, Bell BB, Mast EE, Margolis HS, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329-39. (Pubitemid 41819540)
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129-33.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/.
6. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004;90:2157-66. (Pubitemid 38869723)
7. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines, 4th ed. Orlando, FL: WB Saunders Co.; 2003:299-337.
8. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55.
9. Centers for Disease Control and Prevention. Surveillance data for acute viral hepatitis. Surveillance Summaries, 2007. MMWR 2009;58(SS-3).
10. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol 2010;117:S32-S35.
11. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-22. (Pubitemid 20069919)
12. Kane M, Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr Opin Infect Dis 2002;15:465-9.
13. Muraskin WA. The war against hepatitis B: a history of the international task force on hepatitis B immunization. Philadelphia: University of Pennsylvania Press; 1995.
14. UNICEF. Available from: http://www.unicef.org/supply/index-57476.html. [cited 2011 Dec 3].
15. GAVI Alliance. Available from: http://www.gavialliance.org/. [cited 2011 Dec 3].
16. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550-7.
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. [cited 2011 Dec 3].
18. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. [cited 2011 Dec 3].
19. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005;89:Suppl 2:S4-S12. (Pubitemid 40488754)
20. Sherris J, Wittet S, Kleine A, Sellors J, Luciani S, Sankaranarayanan R, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. Int Perspect Sex Reprod Health 2009;35:147-52.
21. Palefsky J. HPV infection and HPV-associated neoplasia in immunocompromised women. Int J Gynecol Obstet 2006;94(Supp 1):S56-S64. (Pubitemid 46175825)
22. 2 levels. Cancer Prev Res 2012;5:34-40.
23. WHO. New and Under-utilized Vaccines Implementation. Countries using HPV vaccine in national immunization schedule, 2010. http://www.who.int/nuvi/hpv/ decision-implementation/en/index.html. (Accessed on 3 Dec 2011).
24. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:RR-2:1-24.
25. CDC. National and State Vaccination Coverage among Adolescents aged 13 through 17 years-United states 2010. MMWR Morb Mortal Wkly Rep 2011;60:1117-23.
26. GAVI Alliance. Available from: http://www.gavialliance.org/. [cited 2011 Dec 3].
27. GAVI Alliance. GAVI welcomes lower prices for life-saving vaccines. Available from: http://www.gavialliance.org/library/news/press-releases/2011/ gavi-welcomes-lower-prices-for-life-saving-vaccines/. (cited 2011 Oct 18).
28. Lamontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011;89:821-30B.
29. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 2009;33:365-70.
30. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008;336:1056-8. (Pubitemid 351692248)
31. Heffernan ME, Garland SM, Kane MA. Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex Health 2010;7:383-90.
32. UNICEF. State of the World's Children. 2009.
33. Gillison M, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20. (Pubitemid 351480511)
34. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009;2:776-81.
35. Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res 2011;4:1378-84.
36. Centers for Disease Control. Fact sheet on HPV and men. [cited 2011 Oct 18]. Availabe from: http://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm.
37. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008;48:491-9.
38. Chiao E, Giordano T, Palefsky J, Tyring S, Hashem E. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006;43:223-33.
39. Weekly Epidemiological Record (WER). 118: Human papillomavirus vaccines: WHO position paper. WHO 2009;84:117-32.
40. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301. doi: 10.1200/JCO.2011.36.4596.
41. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/ appendices/G/impact-of-vaccines.pdf. [cited 2011 Dec 3].
42. Roush SW, Murphy TV Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63. (Pubitemid 350106654)
43. th Edition April 2011. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/G/impact- of-vaccines.pdf (Accessed on 3 Dec 2011).